Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Financial Results

Every financial results filing by a US-listed company that our alert engine sent, newest first.

8:32 AM ET 8-K
Financial Results HCW Biologics Inc. HCWB

HCW Biologics Financial Results

HCW Biologics reported financial results for the third quarter of 2026, highlighting progress in its HCW9302 Phase 1 clinical study for alopecia areata and the presentation of its TRBC platform molecules at SITC2026. The company recently secured up to $10.0 million in debt financing to support its clinical and preclinical programs through the Phase 1 readout expected in Q1 2027.

Term
Q3 2026

“Progress continues steadily for our clinical study evaluating HCW9302 in alopecia areata, and we are encouraged by results in humans that are consistent with our preclinical studies. We have the support of strong clinical sites who share our passion for developing breakthrough immunotherapeutics. With the addition of a third clinical site, we are hopeful that patient enrollment will maintain a good momentum as we come to the end of the Phase 1 clinical study. We are also excited about the great progress we have made with the molecules we have constructed using our TRBC platform, especially our lead T-cell engager, HCW11-018b, and our lead second-generation immune-checkpoint inhibitor, HCW11-040, which have the potential of revolutionizing treatment for solid tumors and senescence-associated diseases.”

Dr. Hing C. Wong, the Company’s Founder and Chief Executive Officer
8:31 AM ET 10-Q
Financial Results Virginia National Bankshares Corp VABK

Virginia National Bankshares Q3 2026 Results: Net Income $6.56M, Up 43.3% YoY

Virginia National Bankshares Corp reported net income of $6.6 million for the third quarter of 2026, a significant increase from $4.6 million in the same period of 2025. This growth was driven by higher net interest income and a $4.7 million gain on the sale of a limited partnership investment during the nine-month period.

Key figure
Net income $6.56M · +43.3% YoY
8:31 AM ET 10-Q
Financial Results HCW Biologics Inc. HCWB

HCW Biologics Q3 2026 Results: Net Loss of $3.22M, Loss Narrows

HCW Biologics Inc. reported a significant revenue increase to $6.7 million for the nine months ended September 30, 2026, primarily driven by a $3.5 million noncash licensing agreement. Despite this, the company recorded a net loss of $5.0 million for the period and an accumulated deficit of $113.5 million, reflecting ongoing research and development costs and substantial equity dividends to investors.

Key figure
Net loss $3.22M
8:31 AM ET 8-K
Financial Results RenX Enterprises Corp. RENX

RenX Enterprises Financial Results

RenX Enterprises reported record Q3 2026 revenue of $4.48 million, representing 27.5% year-over-year growth and its third consecutive quarter of sequential growth. The company achieved a record gross margin of 34.3% and completed construction of its Microtec mill, with production expected to begin in January 2027.

Term
Q3 2026

“RenX grew revenue every quarter of 2026, expanded gross margin to its best level of the year, and delivered a third straight profitable quarter in Logistics. That is fundamental growth, quarter after quarter, generated by operations.”

David Villarreal, Chief Executive Officer of RenX Enterprises Corp.
8:29 AM ET 8-K
Financial Results HeartCore Enterprises, Inc. HTCR

HeartCore Enterprises Financial Results

HeartCore Enterprises reported Q3 2026 financial results, showing a significant revenue decline to $0.16 million from $1.2 million year-over-year due to fewer successful client IPOs. The company completed its strategic exit from software development services by divesting its interest in HeartCore Luvina to focus on its Go IPO consulting and capital markets advisory business.

Term
Q3 2026

“With the transfer of our interest in HeartCore Luvina completed during the third quarter, we have concluded the portfolio optimization we began earlier this year. HeartCore now operates as a focused Go IPO consulting, capital markets advisory, and financial services company, which we believe allows us to direct management attention and capital toward the areas where we see the greatest long-term opportunity.”

Sumitaka Kanno, HeartCore CEO

“The Nasdaq listing environment remains selective, and a number of our clients have extended their IPO timelines as they work to satisfy stricter exchange and regulatory requirements. We continue to prioritize clients that we believe demonstrate stronger fundamentals, organizational readiness, and a clear path to a U.S. listing, and we are cautiously optimistic that this disciplined approach will support a higher-quality pipeline over time.”

Sumitaka Kanno, HeartCore CEO
8:18 AM ET 8-K
Financial Results Widepoint Corp WYY

Widepoint Financial Results

WidePoint Corporation reported financial results for the third quarter ended September 30, 2026, and provided an update on its DHS CWMS 3.0 contract status. Despite a GAO protest setback, the company was awarded 40 new and replacement task orders valued at $33.7 million during the quarter under existing bridge contracts.

Term
Q3 2026

“I want to acknowledge that the last few months have presented challenges and outcomes that fell short of what we had envisioned for our DHS program. As you know, the Government Accountability Office, or the GAO's decision to sustain the protest filed regarding the pending CWMS 3.0 award, while not unprecedented, was still an unexpected setback.”

Jin Kang, Chief Executive Officer, President and Director

“While delays and setbacks are frustrating, we are well-positioned to withstand near-term headwinds as we await a decision from DHS.”

Jin Kang, Chief Executive Officer, President and Director
8:16 AM ET 10-Q
Financial Results Alx Oncology Holdings Inc ALXO

Alx Oncology Holdings Q3 2026 Results: Net Loss of $21.8M, Loss Narrows

ALX Oncology reported a net loss of $57.7 million for the nine months ended September 30, 2026, an improvement from the $78.8 million loss in the prior year period. The company significantly strengthened its balance sheet through equity offerings, increasing total stockholders' equity to $125.9 million from $26.0 million at the end of 2025.

Key figure
Net loss $21.8M
8:16 AM ET 10-Q
Financial Results US Alliance Corp

US Alliance Q3 2026 Results: Net Loss of $529K, Loss Widens

US Alliance Corp reported a net loss of $820,543 for the nine months ended September 30, 2026, compared to a loss of $795,892 in the prior year period. Total assets remained stable at $149.4 million, while the company saw a significant shift in its investment portfolio toward mortgage loans and a decrease in cash and cash equivalents.

Key figure
Net loss $529K
8:16 AM ET 10-Q
Financial Results Neumora Therapeutics, Inc. NMRA

Neumora Therapeutics Q3 2026 Results: Net Loss of $34.4M, Loss Narrows

Neumora Therapeutics reported a net loss of $34.4 million for the third quarter of 2026, an improvement from the $56.8 million loss in the prior year period. The company's cash and cash equivalents decreased significantly to $85.7 million as of September 30, 2026, compared to $182.5 million at the end of 2025, while total stockholders' equity fell to $18.6 million.

Key figure
Net loss $34.4M
8:16 AM ET 8-K
Financial Results Virtuix Holdings Inc. VTIX

Virtuix Holdings Financial Results

Virtuix Holdings reported Q2 fiscal 2027 financial results featuring 55% sequential revenue growth to $1.2 million, driven by a 105% increase in Omni One revenue following its launch for Meta Quest. The company also announced a non-binding letter of intent to acquire defense technology firm STS International for approximately $12 million to expand its presence in the government and defense sectors.

Term
Q2 2027
8:15 AM ET 10-Q
Financial Results Tancheng Group Co., Ltd. QSJC

Tancheng Group Co Q3 2026 Results: Net Loss of $89.7K, Loss Widens

Tancheng Group Co., Ltd. reported zero revenue for the nine months ended September 30, 2026, as it pivoted from product sales to the development of a cultural tourism project. The company recorded a net loss of $338,896 for the period and maintains a significant accumulated deficit of $2.4 million, raising concerns about its ability to continue as a going concern.

Key figure
Net loss $89.7K
8:13 AM ET 8-K
Financial Results Dawson Geophysical Co DWSN

Dawson Geophysical Financial Results

Dawson Geophysical reported third quarter 2026 financial results, including fee revenue of $10.8 million and a net loss of $5.2 million. The company noted that two large channel crew jobs were delayed from Q3 into Q4 due to government permitting issues, but highlighted a strengthened backlog and renewed demand for seismic data acquisition in North America.

“Although our financial performance fell short of our expectations in the third quarter, I cannot be more excited about how this Company is positioned to capitalize on the renewed demand for seismic data acquisition services in North America. We are observing increased demand in Canada and in the United States across the oil and gas space and in other non-traditional markets, such as Carbon Capture, Utilization, and Storage (“CCUS”) and geothermal, and we are scheduled to start our first geothermal data acquisition in November.”

Tony Clark, Dawson’s President and CEO

“I evaluate the Company’s performance over the long term rather than quarterly, and 2026 will be the third year in a row of increasing top-line revenue, improved gross margins and higher Adjusted EBITDA, and I expect that to continue in 2027.”

Tony Clark, Dawson’s President and CEO
8:13 AM ET 10-Q
Financial Results Idaho Strategic Resources, Inc. IDR

Idaho Strategic Resources Q3 2026 Results: Net Income $2.64M, Down 11.2% YoY

Idaho Strategic Resources reported a significant increase in nine-month revenue to $37.1 million in 2026, up from $27.8 million in 2025, driven by product sales. Net income attributable to the company rose to $12.7 million for the nine-month period, while the company transitioned its investment strategy by transferring $64.2 million of US treasury notes from held-to-maturity to available-for-sale.

Key figure
Net income $2.64M · -11.2% YoY
8:13 AM ET 8-K
Financial Results Veritone, Inc. VERI

Veritone Financial Results

Veritone reported Q3 2026 revenue of $18.6 million, a 30% year-over-year decrease, and a net loss of $19.2 million. Alongside results, the company announced a debt exchange for $38.7 million of convertible notes and a $40 million senior secured term loan commitment from Blue Torch Capital to improve its liquidity position.

Term
Q3 2026

“We have spent the majority of fiscal 2026 taking actions to put Veritone in a stronger financial and operational position. With our newly announced convertible notes exchange and commitment letter, combined with our recent cost reduction efforts, we are on a clear path to greatly improve our financial position and ability to execute our operating model and product strategy.”

Ryan Steelberg, President and Chief Executive Officer of Veritone
8:11 AM ET 8-K
Financial Results Alx Oncology Holdings Inc ALXO

Alx Oncology Holdings Financial Results

ALX Oncology reported third quarter 2026 financial results, ending the period with $147.2 million in cash and investments, which is expected to fund operations through the first half of 2028. The company highlighted clinical progress for evorpacept and ALX2004, with topline data from the ASPEN-09-Breast trial now expected in the second half of 2027.

“Throughout the third quarter, we continued to make significant progress across both the ASPEN-09-Breast and ALX2004 clinical trials. The recent publication of ASPEN-06 results in Nature Medicine further reinforces the promise of evorpacept and our biomarker-driven development strategy.”

Jason Lettmann, Chief Executive Officer of ALX Oncology
8:11 AM ET 10-Q
Financial Results Apnimed, Inc. APMD

Apnimed Q3 2026 Results: Net Loss of $29.5M, Loss Widens

Apnimed, Inc. is a late-stage clinical pharmaceutical company focused on its lead product candidate, Oxnimbi, which has completed Phase 3 clinical trials. The company reports significant operating losses since inception and anticipates requiring substantial additional funding to support its commercialization efforts and regulatory approval processes.

Key figure
Net loss $29.5M
8:09 AM ET 8-K
Financial Results Iambic Therapeutics, Inc. IAM

Iambic Therapeutics Financial Results

Iambic Therapeutics reported third quarter 2026 financial results, highlighting a pro-forma cash position of $455 million following its IPO and upfront payments from AbbVie. The company reported year-to-date collaboration revenue of approximately $24 million and total operating expenses of $108 million. Key operational milestones included the launch of its Enchant v3 AI model and positive Phase 1/2 data for its HER2 inhibitor, IAM1363.

Term
Q3 2026

“Iambic’s mission is to make better technology for better medicines, and we believe that the past several months showed that at work across every part of our business. At ESMO, our updated clinical data showed the intracranial activity and tolerability for IAM1363, and we are preparing to start a registrational trial in 2027, subject to regulatory approval. We submitted the IND and have received a Safe-to-Proceed Letter for a Phase 1/2 trial for IAM217, our second wholly owned and platform-discovered candidate, with an anticipated IND submission for IAM-C1, our CDK2/4 inhibitor, close behind. We launched Enchant v3, a huge advance in the core AI technology that underpins our molecular superintelligence platform, and AbbVie and Bayer each chose to bring our platform to bear on their own discovery work through new Iambic partnerships. Our IPO gives us the resources to advance our pipeline through major inflection points and to keep scaling the platform behind it.”

Tom Miller, PhD, Co-Founder & CEO of Iambic
8:06 AM ET 10-Q
Financial Results International Battery Metals Ltd. IBATF

International Battery Metals Q2 2026 Results: Net Income $2.17M, Down 27.2% YoY

International Battery Metals Ltd. reported a net income of $2.14 million for the six months ended September 30, 2026, primarily driven by a $7.93 million non-cash gain from the change in fair value of warrant liabilities. Despite the net profit, the company experienced an operating loss of $5.78 million and negative cash flow from operations as it continues to market its modular direct lithium extraction (MDLE) technology.

Key figure
Net income $2.17M · -27.2% YoY
8:06 AM ET 10-Q
Financial Results Jasper Therapeutics, Inc. JSPR

Jasper Therapeutics Q3 2026 Results: Net Loss of $144M, Loss Widens

Jasper Therapeutics reported a significant net loss of $148.4 million for the nine months ended September 30, 2026, primarily driven by a $129.5 million charge for acquired in-process research and development. Despite the loss, the company strengthened its liquidity through a financing and acquisition, ending the period with $135.3 million in cash and cash equivalents.

Key figure
Net loss $144M
8:06 AM ET 8-K
Financial Results International Battery Metals Ltd. IBATF

International Battery Metals Financial Results

International Battery Metals reported Q2 fiscal 2027 results, including a net income of $2.2 million driven by a $5.0 million gain in the fair value of warrant liabilities. The company announced plans to build a compact, transportable pilot plant to provide field data for North American resource owners and expects to secure a $12.0 million bridge loan from its largest investor.

Term
Q2 2027

“We continue to evaluate opportunities across North America, including through an active laboratory testing program. Our ongoing discussions with North American resource owners have made clear that one of their biggest challenges is they need field data from their own resources before making investment decisions. To meet that need, we have begun engineering a compact pilot plant that can be deployed at sites quickly, and at a lower cost than our existing demonstration plant.”

Don Bender, Interim Chief Executive Officer
8:05 AM ET 10-Q
Financial Results Adagio Medical Holdings, Inc. ADGM

Adagio Medical Holdings Q3 2026 Results: Turns Profitable, Net Income $17.8M

Adagio Medical Holdings, Inc. reported a significant decrease in cash and cash equivalents from $17.1 million at the end of 2025 to $3.1 million as of September 30, 2026. The company highlighted substantial risks regarding its ability to continue as a going concern and is exploring strategic alternatives to maximize stockholder value.

Key figure
Net income $17.8M
8:05 AM ET 8-K
Financial Results Apnimed, Inc. APMD

Apnimed Financial Results

Apnimed reported third quarter 2026 financial results, highlighting a cash position of $351.8 million following its upsized IPO in August. The company's NDA for AD109 (Oxnimbi) for the treatment of obstructive sleep apnea remains under FDA review with a PDUFA goal date of February 28, 2027.

“We are in a transformational period at Apnimed. With our NDA for AD109 (proposed proprietary name Oxnimbi) under FDA review and a PDUFA goal date of February 28, 2027, we are advancing our launch readiness while continuing to strengthen the clinical story.”

Kevin Lind, Chief Executive Officer of Apnimed
8:04 AM ET 8-K/A
Financial Results Accelevation Holdings Corp. ACCV

Accelevation Holdings Financial Results

Accelevation Holdings Corp. reported Q3 2026 financial results with revenue growing 66% year-over-year to $202.2 million and a significant bookings increase of 364%. The company also issued an amendment to correct errors in its original earnings release regarding SG&A margins and Adjusted SG&A calculations.

“At Accelevation, we design, manufacture, and install mission-critical infrastructure for customers who rely on our speed and certainty of delivery, and our third quarter results reflect the strength of our operating model and underlying markets.”

Michael Rubiera, Co-Founder and Chief Executive Officer

“We delivered strong growth, profitability, and cash generation in the quarter. Revenue increased more than 60%, bookings grew more than 350%, backlog rose to approximately $1.7 billion, and Adjusted EBITDA margins approached 19% following a weaker first half of the year.”

Ken Krause, Chief Financial Officer
8:03 AM ET 8-K
Financial Results Adagio Medical Holdings, Inc. ADGM

Adagio Medical Holdings Financial Results

Adagio Medical reported Q3 2026 financial results, highlighting a net income of $17.8 million primarily driven by a $23.0 million gain from the change in fair value of warrant liabilities. The company also announced that its Board of Directors has initiated a formal process to explore strategic alternatives to maximize shareholder value while continuing clinical progress on its vCLAS Ultra System.

Term
Q3 2026

“The third quarter was defined by progress in the clinical and regulatory programs that we believe are the foundation for the value of Adagio and our ULTA platform. Our PMA application for the vCLAS Ventricular Ablation System remains under FDA review, and we initiated the vCLAS Ultra IDE study, which builds on the FULCRUM-VT results with a faster, more maneuverable next-generation catheter.”

Todd Usen, Chief Executive Officer of Adagio Medical

“As the Board’s review of strategic alternatives continues, we have aligned our cost structure around these prioritized programs and remain focused on maximizing value for our shareholders.”

Todd Usen, Chief Executive Officer of Adagio Medical
8:02 AM ET 10-Q
Financial Results Suncrete, Inc. RMIX

Suncrete Q3 2026 Results: Net Income $78K, Down 98.3% YoY

Suncrete, Inc. reported a significant revenue increase to $300.0 million for the nine months ended September 30, 2026, compared to $130.8 million in the prior year, driven by acquisition activity. However, the company realized a net loss attributable to common stockholders of $55.0 million for the period, primarily due to higher interest expenses and substantial acquisition-related costs.

Key figure
Net income $78K · -98.3% YoY
8:02 AM ET 10-Q
Financial Results Montauk Renewables, Inc. MNTK

Montauk Renewables Q3 2026 Results: Net Income $2.14M, Down 58.9% YoY

Montauk Renewables reported total operating revenues of $150.6 million for the nine months ended September 30, 2026, up from $133.0 million in the prior year. The company achieved a net income of $2.37 million for the period, recovering from a net loss of $0.75 million in 2025, despite an operating loss of $2.6 million driven by higher operating and maintenance expenses.

Key figure
Net income $2.14M · -58.9% YoY
8:01 AM ET 10-Q
Financial Results Nuvera Communications, Inc. NUVR

Nuvera Communications Q3 2026 Results: Net Loss of $176K, Loss Narrows

Nuvera Communications reported total operating revenues of $17.4 million for the third quarter of 2026, a slight decrease from $18.0 million in the prior year, primarily due to lower A-CAM/FUSF and video service revenues. Despite the revenue dip, operating income improved to $2.66 million as the company reduced operating expenses, though it ultimately recorded a net loss of $176,261 for the quarter due to high interest expenses.

Key figure
Net loss $176K
8:01 AM ET 10-Q
Financial Results TerraVolt Holdings, Inc. GEDC

TerraVolt Holdings Q3 2026 Results: Net Loss of $1.66M, Loss Widens

TerraVolt Holdings, Inc. reported a net loss of $3.9 million for the nine months ended September 30, 2026, compared to a $5.7 million loss in the prior year period. The company is currently pre-revenue and focused on financing and constructing proposed data center operations, with total assets increasing to $13.55 million primarily due to new restricted cash and other assets.

Key figure
Net loss $1.66M
8:01 AM ET 8-K
Financial Results Jasper Therapeutics, Inc. JSPR

Jasper Therapeutics Financial Results

Jasper Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided a corporate update following its acquisition of Kira Pharmaceuticals. The company highlighted progress in its Phase 2 renal basket study for vensobafusp alfa (KP104), including completed enrollment in the IgA nephropathy cohort and the dosing of the first patient with IC-MPGN.

“We have made progress advancing our development programs in recent months following our acquisition of Kira Pharmaceuticals, highlighted by the recent completion of enrollment in the first cohort of our Phase 2 renal basket study evaluating vensobafusp alfa (KP104) in patients with IgA nephropathy (IgAN).”

Jeet Mahal, President and Chief Executive Officer of Jasper

“We believe that the bifunctional ability of vensobafusp alfa to inhibit both the alternative and terminal complement pathways may provide the potential for differentiated onset and efficacy in complement driven diseases, and we look forward to presenting interim data from the IgAN cohort in the fourth quarter of 2026 and additional updates from our pipeline programs in 2027.”

Jeet Mahal, President and Chief Executive Officer of Jasper
8:01 AM ET 8-K
Financial Results Venu Holding Corp VENU

Venu Holding Financial Results

Venu Holding Corp reported its Q3 2026 financial results, highlighting a 59% increase in total assets to $587.6 million since year-end 2025. The company is transitioning from a construction phase to an operational phase with the upcoming opening of the Regent Bank Amphitheater on New Year's Eve and the Sunset Amphitheater McKinney in Q1 2027.

Term
Q3 2026

“Next quarter, VENU moves from building to operating. With two venues coming online, we expect to see a meaningful step up in ticketing, food and beverage, and sponsorship revenue in fiscal 2027. Content drives all of it, and we already have more than 110 holds on the calendar across our portfolio.”

J.W. Roth, Founder, Chairman, and Chief Executive Officer

“What you see in our results today is the cost of bringing more than $600 million in assets online by mid-2027, and we continue to expect to be in a position to provide financial guidance in the middle of next year.”

J.W. Roth, Founder, Chairman, and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.